Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)
- Authors
- Hur, Seung-Ho; Kim, In-Cheol; Won, Ki-Bum; Cho, Yun-Kyeong; Yoon, Hyuck-Jun; Nam, Chang-Wook; Kim, Kwon-Bae; Kim, Min-Seok; Park, Jincheol; Rha, Seung-Woon; Chae, Shung-Chull; Kim, Young-Jo; Kim, Chong-Jin; Cho, Myeong-Chan; Jeong, Myung-Ho; Ahn, Young-Keun; Kim, Hyo-Soo; Ahn, Tae-Hoon; Seung, Ki-Bae; Jang, Yangsoo; Yoon, Jung-Han; Seong, In-Whan; Hong, Taek-Jong; Bae, Jang-Ho; Park, Seung-Jung
- Issue Date
- May-2016
- Publisher
- WILEY
- Citation
- CLINICAL CARDIOLOGY, v.39, no.5, pp.276 - 284
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL CARDIOLOGY
- Volume
- 39
- Number
- 5
- Start Page
- 276
- End Page
- 284
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/88700
- DOI
- 10.1002/clc.22525
- ISSN
- 0160-9289
- Abstract
- Background: Despite improved long-term safety of biodegradable polymer (BP) drug-eluting stents (DES) compared to first-generation durable polymer (DP) DES, data on the safety and efficacy of BP-DES compared with second-generation (2G) DP-DES in patients with acute myocardial infarction (AMI) are limited. Hypothesis: To evaluate the safety and efficacy of BP-DES compared with 2G-DP-DES in the higher stent thrombosis (ST) risk setting of AMI. Methods: A total of 3359 AMI patients who received either BP-DES (n=261) or 2G-DP-DES (n=3098) were included from the Korea Acute Myocardial Infarction Registry (KAMIR). Differences in baseline clinical and angiographic characteristics were adjusted using a 1:5 propensity score matching analysis (n=261 for BP-DES and n=1305 for 2G-DP-DES). The primary outcome was the incidence of major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction (re-MI), and target vessel revascularization (TVR). The rate of definite or probable ST was also investigated. Results: In adjusted analysis, there was no significant difference between the 2 groups in baseline clinical and angiographic characteristics; 2-year MACE (10.7% and 9.9% in the BP-DES group and 2G-DP-DES group, respectively, P =0.679); ST incidence (0.8% vs 0.9%, respectively, P =1.0), and rates of all-cause death, re-MI, and TVR. By multivariate analysis, old age, diabetes mellitus, renal dysfunction, and left ventricular dysfunction were the independent predictors of MACE after BP-DES or 2G-DP-DES implantation. Conclusions: BP-DES and 2G-DP-DES appear to have comparable 2-year safety and efficacy for the treatment of AMI. However, longer-term follow-up is needed.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/88700)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.